Hypersensitivity to the active substance or to any of the excipients1
Active clinically significant bleeding1
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk1
Lesion or condition if considered a significant risk factor for major bleeding; this may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities1
Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.), except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when unfractionated heparin is given during catheter ablation for atrial fibrillation1
ELIQUIS is approved for a broad range of indications1
Please click here to access the ELIQUIS Patient Information Leaflet.
UFH = Unfractionated Heparin
ELIQUIS® (apixaban) Summary of Product Characteristics.
You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.
All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.
Date of preparation: February 2020